Market Herald logo


Be the first with the news that moves the market

Neurotech’s strategic adviser, Dr. Adrian Attard Trevisan, has been found guilty of misconduct after the Malta Times published an article suggesting he never completed a PhD in neuroscience. 

Dr. Adrian Attard Trevisan has admitted to his wrong-doing, stating he mislead the public and has never completed a PhD in Neuroscience, from the University of College London. But instead, Dr. Attard Trevisan has a completed PhD in Human Physiology from the University of Milan.

As a result, Dr. Adrian Attard Trevisan has resigned, as the director of Neutrotech Limited, in June 2018 and no longer has any involvment with the company and its board or management team.

“Neurotech’s flagship product Mente is the result of much more than the work of one person. Neurotech’s dedicated Mente team has worked for many years to create, refine and improve the device and its therapeutic outcomes – and that work continues today, and into the future,” Neurotech International Limited.

Please find announcement attached:

NTI by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.